sulunz Gillead bought a compound in same arena as BIT Hep C market , they achieved 85 % success in clinical three trials , we achieved similar result in clinical 2 trials , Gilleads product since , has not been as successful as anticipated their packaging now caries scull and cross bones as it can kill in very certain circumstances . We do not have those side effects . Our product I would suggest is probably better , but we came to the market with testing too late and were not quick enough . Timing on HIV is a lot better
BIT Price at posting:
4.1¢ Sentiment: Buy Disclosure: Held
